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Background: Glycodelin is a cell surface glycoprotein offering a unique gender specific carbohydrate configuration.
Sialylated carbohydrate structures, which are unusual for mammals, characterize Glycodelin isolated from amniotic
fluid (Glycodelin A, GdA). Glycodelin in general exerts multiple, partly opposing functions ranging from
immunosuppression to cell differentiation. As these markedly influence tumorigenesis, this study aimed to clarify
whether expression of different Glycodelin isoforms is related to clinicopathological characteristics and prognosis of
ovarian cancer patients. Further the use of Glycodelin as a serum marker in benign and malignant ovarian diseases
was evaluated.
Methods: Ovarian cancer specimens (n = 152) were stained for Glycodelin with carbohydrate and peptide specific
antibodies. Associations between Glycodelin expression and histological grading, FIGO stage as well as patient’s
prognosis were examined. Glycodelin was correlated to expression of gonadotropin receptors and mucin-1, which
are discussed as ovarian cancer tissue markers. In addition, Glycodelin serum concentrations were analyzed in
patients suffering from benign (n = 73) or malignant (n = 38) ovarian neoplasias.
Results: Glycodelin A was found to be an independent prognostic marker for poor prognosis in advanced ovarian
cancer patients. GdA staining correlated with gonadotropin receptor (FSHR and LHCGR) and with hCG expression.
Gd expression showed a positive correlation with a tumour-associated epitope of mucin 1 (TA-MUC1). Further,
compared to ovarian cancer, serum Gd was increased in patients with benign ovarian tumors.
Conclusion: Glycodelin A might be related to tumor aggressiveness and poor clinical outcome in advanced
epithelial ovarian cancer. Glycodelin serum levels found in patients suffering from benign ovarian tumors, might
contribute to a more global attenuation during progression of these precursor lesions.
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Epithelial ovarian cancer (EOC) represents the most le-
thal malignancy of the female genital tract. Nowadays
ovarian cancer patients’ prognosis mostly relies on com-
pleteness of surgical tumor resection [1,2], clinical sta-
ging and histological tumor grading[3]. Thus there is a
compelling need to identify and validate tumor specific
antigens which are suitable to individualize therapeutic
strategies. Interestingly, during EOC evolvement and* Correspondence: udo.jeschke@med.uni-muenchen.de
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reproduction in any medium, provided the orprogression host anti-tumor immune defense seems to be
actively blocked by tumor derived mediators. By creating
this highly suppressive environment, EOC manages to ex-
tensively grow and spread in the peritoneal cavity.
Glycodelin (Gd), a potent immunosuppressive agent of
the reproductive tract, is supposed to contribute to this
immune tolerant phenotype. Gd is a glycoprotein whose
immune-regulatory actions have been highlighted within
different biological processes [4-6] and which is abun-
dantly found in the female reproductive tract [7-9].
Structure wise it is part of the lipocalin superfamily and
exerts its potent immune-regulatory activity via its
unique, heavily sialysiated glycosylation pattern. ApartLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Patients‘ characteristics; Details on patients



















n.a. = data on grade/FIGO stage were not available.
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during implantation of the fetal semiallotransplantant it
is also expressed by malignant tissues and contributes
to the tumor-micromilieu [10,11]. Nevertheless, the
physiological importance of Gd-expression in malig-
nant diseases remains unknown. Gd is one of very few
proteins that show a gender specific glycosylation pat-
tern. Glycodelin, isolated from amniotic fluid (glycode-
lin A, GdA) is composed of two identical subunits
closely connected by non-covalent bonds and a carbo-
hydrate content of 17.5% [12]. A similar glycoprotein,
Glycodelin S (GdS), was found in seminal plasma, but
with a different glycosylation compared to GdA. While
GdA is heavily sialylated, GdS is characterized by
fucose-rich carbohydrate structures [13].
In the current study Gd was detected by antibodies
raised against peptide sequences, which are not gender
specific or specific for GdA or GdS, and a GdA specific
monoclonal antibody [14,15]. In this work we aimed to
clarify whether Gd expression in EOC is of prognostic
significance. Further Glycodelin was correlated to ex-
pression of gonadotropin receptors and Mucin-1, which
are discussed as ovarian cancer tissue markers. Finally
we tested whether Glycodelin might be a potentially use-
ful serum biomarker to detect ovarian cancer.
Materials and methods
Tissue acquisition
All tissue samples (n = 152) were got at surgery for primary
EOC in patients treated at the Department of Obstetrics
and Gynecology of the Ludwig-Maximilians-University
Munich between 1990 and 2002. Specimens were assessed
by two gynecological pathologists according to the criteria
of the FIGO and the World Health Organization (WHO).
Follow up data, which were received from the Munich
Cancer Registry, and patients’ characteristics are listed in
Table 1.
Sera of 111 patients, who underwent surgery at the
Department of Obstetrics and Gynecology of Ludwig-
Maximilians-University Munich between 2002 and 2005,
were collected before surgery. Histological diagnoses (Table 1
B, benign ovarian diseases, n = 73 and EOC, n = 38) were
made by gynecological pathologists. Written informed
consent was obtained from all patients before surgery. Be-
nign ovarian diseases were set up of cystic lesions (n = 21;
serous cysts, mucinous cysts, follicle cysts, inclusion cyst,
corpus luteum cysts), inflammatory diseases (n = 18; endo-
metriosis cysts, sactosalpinx) and benign tumors (n = 34;
serous and mucinous cystadenofibroma, fibroma, teratoma).
Sera of EOC patients (n = 38) were analyzed in parallel.
Immunohistochemistry
Tissue specimens were dewaxed in xylol and endogen-
ous peroxidase was quenched with 3% hydrogen peroxidefor 20 min. Following epitope retrieval, slides were blocked
and antibody staining was performed using the Vectastain
elite kit (Vector Laboratories, Burlingame, USA) according
to the manufacturer’s protocol. For details on blocking and
staining procedure see Table 2. Finally, slides were stained
with diaminobenzidine (Dako, Hamburg, Germany), coun-
terstained in Mayer's acidic hematoxylin and cover slipped
with Consul Mount (Thermo Shandon, Pittsburgh, PA).
Isotype matched mouse IgG instead of the primary anti-
body was used as a negative control and tissue positive
controls are listed in Table 2. The signal was quantified
using a semi quantitative method [16] by two examiners.
At a glance the immuno-reactive (IR)-score quantifies
staining intensity (1 = low, 2 = moderate, 3 = strong) and
percentage of stained cells (0 = no, 1 = less than 10%, 2 =
10% - 50%, 3 = 51% - 80%, 4 = 81% - 100% stained cells).
Multiplication of these values results in the IR-score ran-
ging from 0 (negative) to 12 (strongly positive). Antibody
staining used to calculate Spearman’s rho are either pub-
lished [17,18] (LHCGR, FSHR, hCG) or are in press
(PankoMabGEXTM).
Analysis of Gd serum levels
Sera were collected prior to surgery and stored at -
80°C. Analysis was performed using a competitive en-
zyme immune assay (EIA) principle. Briefly, plates
were coated with antibodies (Table 2), which were rose
against a peptide sequence localized in the C-terminal
Table 2 Antibodies used for immunohistochemistry and EIA; GdC15, GdQ13 and GdN20 were purchased from




Epitope retrieval Blocking Dilution Incubation Reaction system
used for detection
GdC15 (SCBT) C-terminal goat/polyclonal Proteinase K
(30 min, RT)
UV-Block (45 min) 1:1000 (UV Block) 30 min (RT) Vectastain elite kit
(goat IgG)
GdQ13 (SCBT) C-terminal goat/polyclonal citrate buffer
(pH 6, 5 min,
pressure cooker)






mouse/ monoclonal citrate buffer




1:3000 (DAKO dil.) o.n. (4°C) Vectastain elite kit
(mouse IgG)





Blocking Dilution Incubation Reaction system
used for detection
GdQ13 (SCBT) C-terminal goat/ polyclonal GdQ13-P (SCBT) 1% BSA, 0.5%
NaN3 in PBS
1.5 ng/ml 1 hour (RT) POD-strepavidin
GdN20 (SCBT) N-terminal goat/ polyclonal GdN20-P (SCBT) 1% BSA, 0.5%
NaN3 in PBS
6 ng/ml 1 hour (RT) POD-strepavidin
rt = room temperature, BSA = bovine serum albumin, PBS = phosphate buffered salt solution, o.n. = over night, POD = horse radish peroxidase.
Competing peptides came from SCBT as well and were biotinylated by the manufacturer; unmodiefied GdQ13-P, GdN20-P were used for setting up the standard
curve. Preparation of GdA is published in Jeschke et al. 2006. Epitope retrieval: Proteinase K was from Quiagen (Hilden, Germany), citrate buffer contained 0.1 M
citric acid and 0.1 M sodium citrate in distilled water (pH 6.0). Blocking: UV-Block was purchased from Thermo Scientific (Bonn, Germany) and horse serum was a
component of the Vectastain elite kit (Vector Laboratories, Burlingame, USA).
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tein core, over night at RT and blocked in blocking so-
lution for 30 min. Following washes with PBS plates
were incubated with biotinylated Gd standard peptides
(GdN20 peptid 6 ng/ml; GdQ13 peptid 1.5 ng/ml) for
1 hour followed by washes in PBS. Serum was diluted
1/2 in PBS and applied onto the plate for 1 hour to
perform the competition step. After washes with PBS
the plate was incubated with POD streptavidine for
2 min before the reaction was stopped with 1 N sulphuric
acid. The readout was performed using an ELISA Reader
Dynex MRX (Dynex Technologies, Chantilly, VA). Amni-
otic fluid or just blocking solution was used as positive
and negative controls, respectively.
Statistical analysis
Data were analysed employing the SPSS (v19, IBM,
Armonk, New York) statistic software for MS windows.
Statistical significance for pair wise comparisons of
unlinked non parametric values was determined by
Mann–Whitney-U test whereas differences among three
or more groups were tested using Kruskal-Wallis one-
way analysis of variance by ranks, respectively. Survival
and recurrence free survival was plotted in accordance
with Kaplan-Meier survival analysis. Correlations were
assessed using Spearman’s rho and gamma correlation
coefficient for two independent variables. Statistical sig-
nificance for all tests was assumed for p < 0.05 and data
are presented as mean ± standard error.Results
Patients’ characteristics and Glycodelin expression
34 patients presented with early disease in stage I (FIGO I).
10 patients had FIGO stage II and 103 patients underwent
surgery because of suspected ovarian cancer involving the
peritoneal cavity (100 patients FIGO stage III and 3
patients stage IV). All patients who suffered from EOC
staged FIGO II - IV received carboplatin and paclitaxel as
chemotherapy after surgery. Histological 53 tumors were
assigned with WHO grade G3, 50 with G2 and another 37
were classified as G1. Mean follow-up time was 11.03 ±
0.58 years and mean overall survival 7.12 ± 0.63 years. 27
relapses and 102 deaths were documented.
Gd was detected by three different antibodies (Figure 1),
which recognize distinct peptide epitopes of Gd or tar-
get GdA specifically. Both peptide antibodies showed
strong to moderate staining (mean IRS GdQ13 = 5.35 ±
0.18; mean IRS GdC15 = 5.86 ± 0.20) which was equally
distributed within the four EOC subtypes examined
(Figure 1 B, C, D). However GdA staining in general
was much less intense (mean IRS = 1.31 ± 0.13) and
showed significantly different staining within subtypes
(p = 0.004) and highest expression (p = 0.007) in mucin-
ous (mean IRS = 3.33 ± 0.89) compared to serous, clear
cell and endometrioid carcinomas (Figure 1 A, D).
Interestingly, Gd staining (IRS > 0) determined by the
peptide specific antibodies (GdC15, GdQ13) was found
in 100% of the tissue sections examined, while GdA sig-
nal was just detected in 58.6%.
Figure 1 Immunohistochemical staining of GdA (A), GdQ13 (B) and GdC15 (C). Representative images of GdA (A), GdQ13 (B) and GdC15 (C)
are shown. GdA expression in mucinous cancers was significantly higher than in the remaining entities (D; p = 0.007). Mean IR-scores for GdA,
GdQ13 and GdC15 are shown (D); error bars represent standard error. Scale bar in B equals 100 μm (50 μm in insert) and applies to A - C.
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clinicopathological criteria and patients’ prognosis
For the peptide specific antisera GdC15 and GdQ13 a
strong correlation in between the two (Table 3) was
observed (p < 0.001). Expression of GdC15, GdQ13 and
GdA epitopes rose with positivity for PankoMabGEXTM
(GdC15, p = 0.007; GdQ13, p = 0.010; GdA, p = 0.004),
which recognizes a special tumour-associated epitope
on MUC1, TA-MUC1, that either localizes to the cell
membrane (mPankoMabGEXTM) or cytoplasm (cPan-
koMabGEXTM). Furthermore GdA staining correlated
with gonadotropin receptor (FSHR, p = 0.031; LHCGR,
p = 0.048) and hCG (p = 0.027) expression. Statistical
analysis revealed no correlation of either GdA or GdQ13
antibodies staining with known prognostic markers in
EOC, namely histological grade or FIGO stage. GdC15
was positively correlated to FIGO stage (p = 0.048).Table 3 Correlations between GdC15, GdQ13 and GdA; Corre
using Spearman’s rho test for two independent variables
GdA GlycC15 Gl
Spearman's rho GdA Correlation Coefficient 1.000 -.142 -.0
Sig. (2-tailed) — .081 .50
GlycC15 Correlation Coefficient -.142 1.000 .45
Sig. (2-tailed) .081 <
GlycQ13 Correlation Coefficient -.054 .456** 1.0
Sig. (2-tailed) .508 < .001 —
A correlation coefficient is presented and statistical significance for all tests was assGlycodelin A predicts prognosis in EOC patients
Whether Gd protein expression is useful to predict
patients’ prognosis was analyzed by drawing Kaplan-
Meier plots. Low expression - in respect of median ex-
pression IR-scores - was defined as IRS (GdA) ≤ 1; IRS
(GdQ13) ≤ 4; IRS (GdC15) ≤ 4. In Kaplan-Meier analysis
patients with GdA-positive advanced EOC (stage III and
IV) had a significantly poorer overall-survival (log rank,
p = 0.014, Fig. 2 A) and five-year survival (log rank,
p = 0.009) than patients with GdA-negative tumors. In
these patients with advanced stage ovarian cancer GdA
positivity predicted significantly shorter recurrence free sur-
vival (log rank, p = 0.038) when compared to GdA negative
tumors (Figure 2 B). In stage I and II no such difference
could be shown. Further, GdA expression was analyzed in
advanced staged patients whose survival after first diagnosis
was longer than ten years (n = 7). Interestingly, none oflations between GdC15, GdQ13 and GdA were assessed
ycQ13 LHCGR FSHR hCG mPankoMabGEX cPankoMabGEX
54 .162* .178* .187* .045 .241**
8 .048 .031 .027 .596 .004
6** -.027 .155 -.045 .228** -.094
.001 .740 .061 .598 .007 .270
00 .118 .080 .047 .217** -.128
.152 .338 .585 .010 .131
umed for p < 0.05. * represents p < 0.05, ** represents p < 0.01.
Figure 2 Cumulative survival (A), and cumulative recurrence free survival (B) of patients who underwent surgery for EOC, were plotted
in accordance with Kaplan-Meier survival analysis. Patients who presented with advanced stage (FIGO III, IV) cancer had significantly less
favorable prognosis if their tumor expressed GdA (A) and their cumulative recurrence free survival was also significantly shortened (B). Statistical
significance for all tests was assumed for p < 0.05.
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GdC15 nor GdQ13 were related to patients’ prognosis
regarding overall survival or recurrence free survival,
respectively.
Serum Glycodelin concentrations
Sera (n = 111) came from patients either presenting with
benign (n = 73) or malignant (n = 38) ovarian diseases.
Ovarian cancer patients mostly presented at stage III
(FIGO I: 16.0%, FIGO II: 12.0%, FIGO III: 56.0% and
FIGO IV: 16.0%). Benign neoplasias were further sub clas-
sified into simple ovarian cysts (n = 21), endometriosis
and inflammatory diseases (n = 18) and benign ovarian
tumors (n = 34). Serum Gd concentrations wereFigure 3 Analysis of Gd serum concentrations by EIA. Gd concentratio
GdQ13 (B). Bar charts represent mean Gd concentrations [ng/ml] and error
patients with benign and malignant ovarian tumors as measured by GdQ1
was assumed for p < 0.05.determined by EIA using the two peptide antibodies
GdN20 and GdQ13 (Figure 3 A, B) for targeting the N -
and C-term of Gd, respectively. Gd was detected in 100%
(GdN20) and 99.1% (GdQ13) of all sera. Significantly
higher Gd concentrations (Figure 3 A, B) were found in
sera collected from patients with benign ovarian tumors
when compared to those with ovarian cancer (GdN20:
p = 0.003, 10.84 ± 0.92 ng/ml vs. 15.81 ± 1.50 ng/ml
and GdQ13: p = 0.001, 3.53 ± 0.40 ng/ml vs. 6.00 ±
0.56 ng/ml). GdQ13 (Figure 3 C) and GdN20 turned out
to sensitively distinguish sera of patients with benign ovar-
ian tumors with acceptable specificity (Figure 3 C; GdQ13:
AUC = 0.729 ± 0.59, p = 0.001, 95% CI: 0.61 - 0.85; GdN20:
AUC = 0.705 ± 0.06, p = 0.003, 95% CI: 0.58 - 0.83). Nons were determined by two different EIA assays using GdN20 (A) and
bars represent standard errors. Gd concentrations in sera derived from
3-EIA are plotted as ROC-curve (C). Statistical significance for all tests
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observed between patients presenting with malignant ovar-
ian cancer, inflammatory ovarian diseases or ovarian cysts.
Discussion
This study found that GdA independently predicts un-
favorable prognosis in advanced stage ovarian cancer
patients. Gd has already been published to correlate with
less favorable clinical presentation in breast [19] and
lung cancer [20], though controversial results were
observed in ovarian cancer patients [21]. However a
common problem in research on Gd is that most com-
mercially available antisera were raised against peptide
epitopes. Since gender specific glycosylation pattern cru-
cially determines Gd-protein function [22], we employed
GdA specific staining [14,15]. Remarkably, just GdA cor-
related with patients’ prognosis (Figure 2) and GdA was
much more selectively distributed than the peptide epi-
topes (Figure 1). Thus we hypothesize, that the specific
glycosylation pattern of GdA and not necessarily just its
presence as determined by the peptide specific antisera,
is responsible for its tumor promoting activity. Therefore
GdA might be an interesting marker to discriminate be-
tween high risk and low risk patients in advanced ovar-
ian cancer (stage III and IV). A former study showed
that Gd is also secreted to ascites fluid of ovarian cancer
patients and that this Gd has significant differences in
its structure of sialyl Lewis-type oligosaccharides com-
pared to GdA. Additionally, ascites Gd inhibits IL-2 sti-
mulated proliferation of peripheral blood leucocytes and
inhibits adhesion of SLeX-positive cells to E-selectin.
Therefore, Gd could act as an inhibitor of lymphocyte
activation and/or adhesion in ovarian cancer [23].
As several studies proofed the immune suppressive ef-
fect of GdA [6,11], we suppose that GdA interferes with
host anti tumor immune defense in EOC as well. Be-
sides, it is widely accepted, that EOC has the ability to
escape immune rejection by creating an immune sup-
pressive environment [24]. Thus expression of the
immunomodulatory GdA in ovarian carcinomas might
contribute to permit immunological destruction of ma-
lignant cells and therefore might be related to tumor
aggressiveness and poor clinical outcome.
Furthermore GdA staining correlated with gonadotropin
receptor (FSHR and LHCGR) and with hCG expression it-
self (Table 3). There are only few studies on human chori-
onic gonadotropin and its receptor expression in ovarian
cancer tissue [25,26]. In a recent study we found an
opposed prognostic value of LHCGR and FSHR in ovarian
cancer [17] in almost the same panel of patients as
described within this study. GdA and hCG stimulate each
other in a positive feedback mechanism in the placental de-
cidua/trophoblast cell system as described earlier [27,28].
Results obtained within this study seem to confirm formerresults of GdA - hCG interaction. Gd expression showed
also a positive correlation with a tumour-associated epitope
of MUC1 (TA-MUC1), which was stained by the Panko-
MabGEXTM antibody. This epitope was found to be ster-
oid hormone receptor dependent in breast cancer [29].
Because it is known that Gd expression is also regulated
by steroid hormones [30], there could be a common
regulation pathway for both Gd and TA-MUC1.
The use of Gd as a serum biomarker in ovarian cancer
patients has been controversially discussed [31,32]. As Gd
might interfere with tumor development, we decided to
examine precursor lesions as well, which turned out to be
characterized by elevated serum Gd levels. Interestingly in
sera collected from ovarian cancer patients Gd levels were
not significantly altered compared to cystic or inflamma-
tory diseases. Benign ovarian tumors are part of a multi-
step process leading to low grade invasive ovarian cancer
[33]. Gd mediated immune attenuation has been described
during pregnancy [34-36] as well as in inflammatory pro-
cesses [37]. Thus, besides of it pathophysiologic role, Gd
might be an interesting to detect benign or inflammatory
changes in the ovaries, but the detection of GdA with its
unique glycosylation may be a more suitable serum mar-
ker for ovarian cancer patients.
Conclusion
GdA is related to tumor aggressiveness and poor clinical
outcome in advanced ovarian cancer. GdA might be an
interesting marker to discriminate between high risk and
low risk patients in stage III and IV ovarian cancer.
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